The GNPDA1 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for studying glucosamine-6-phosphate deaminase 1 (GNPDA1) in human cells. This product derives from the HEK293T host, with targeted disruption of the GNPDA1 gene, enabling loss-of-function investigations without describing the specific editing pattern. The polyclonal pool offers a heterogeneous knockout background suitable for assessing population-level metabolic and signaling effects.
HEK293T cells are a human embryonic kidney epithelial line transformed with adenovirus E1A and expressing SV40 large T antigen, conferring high transfection efficiency and robust protein production capacity. Widely used for viral packaging and recombinant protein expression, HEK293T provides an optimal system for interrogating metabolic enzymes due to its active hexosamine biosynthetic pathway and amenability to genetic manipulation.
GNPDA1 catalyzes the deamination of glucosamine-6-phosphate to fructose-6-phosphate, a key step controlling flux through the hexosamine biosynthetic pathway. This reaction regulates the availability of UDP-N-acetylglucosamine (UDP-GlcNAc), the sugar donor for O-GlcNAcylation of proteins. GNPDA1 activity is influenced by glucosamine-6-phosphate substrate levels, nutrient signaling (insulin, glucose), and the transcription factor Sp1. Downstream targets include O-GlcNAcylated proteins such as c-Myc, p53, and Sp1, linking metabolic status to transcriptional regulation. The enzyme forms homo-oligomeric complexes and functionally interacts with GFPT1/2, the rate-limiting enzymes of the pathway. Representative pathway components include GFPT1, GFPT2, GNPNAT1, PGM3, UAP1, OGT, and OGA, highlighting its integration with amino sugar metabolism and O-GlcNAc cycling.
In HEK293T cells, GNPDA1 knockout disrupts glucosamine salvage, leading to altered hexosamine pathway flux and UDP-GlcNAc levels. This model is particularly relevant for studying O-GlcNAc signaling dynamics, as HEK293T cells exhibit active protein glycosylation. The polyclonal nature allows the observation of varied O-GlcNAcylation patterns and metabolic adaptations without clonal selection biases, offering a system-level view of pathway perturbations. The knockout may shift glycolytic intermediates and influence metabolic reprogramming, providing insights into cancer metabolism and metabolic syndrome.
This knockout model supports diverse experimental applications including hexosamine pathway flux analysis, investigation of O-GlcNAc modifications on transcription factors, and metabolic engineering of glycosylation. Researchers can employ western blotting to quantify O-GlcNAc and OGT/OGA levels, HPLC or LC-MS for UDP-GlcNAc quantitation, and enzyme activity assays to confirm GNPDA1 deamination loss. Immunofluorescence visualizes O-GlcNAc localization changes, while RT-qPCR and RNA-seq enable transcriptomic profiling of pathway genes. Flow cytometry can assess metabolic markers and apoptosis. These tools facilitate studies on neuronal development, epileptic encephalopathy, and cancer metabolic reprogramming. For further assistance, please contact Ascent Research.
